Five sites across the U.S. are now participating in the Phase 1b study

美国有五个地点正在参与1b期研究

Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the addition of the University of Pittsburgh Medical Center (UPMC) Department of Dermatology in Pittsburgh, PA as a clinical trial site for its lead product candidate, PH-762..

马萨诸塞州马尔伯勒--（新闻文件公司-2024年7月8日）-临床阶段生物技术公司Phio Pharmaceuticals Corp.（纳斯达克：Phio），其专有的INTASYL®siRNA基因沉默技术旨在使免疫细胞更有效地杀死肿瘤细胞，今天宣布增加宾夕法尼亚州匹兹堡匹兹堡大学医学中心（UPMC）皮肤科，作为其主要候选产品PH-762的临床试验场地。。

The Phase 1b study recently received a positive safety recommendation from the Safety Monitoring Committee to escalate the dose in the next phase of the study. The clinical trial is currently enrolling patients for the 2nd cohort.

1b期研究最近收到了安全监测委员会的积极安全建议，以在研究的下一阶段提高剂量。该临床试验目前正在招募第二组患者。

The UPMC Department of Dermatology joins four other sites engaged in the clinical study: The George Washington University-Medical Faculty Associates in Washington, D.C; Banner MD Anderson Cancer Center in Gilbert, Arizona; Integrity Research Clinical Associates in Delray Beach, Florida; and Centricity Research in Dublin Ohio..

UPMC皮肤科加入了其他四个参与临床研究的网站：华盛顿特区乔治华盛顿大学医学院协会；亚利桑那州吉尔伯特的Banner MD安德森癌症中心；佛罗里达州Delray Beach的Integrity Research Clinical Associates；以及俄亥俄州都柏林的中心研究。。

'We are excited to conduct our study with these five clinical sites, all of whom have a very keen interest in immuno-oncology and are leading centers in skin cancer,' said Robert Bitterman, CEO of Phio Pharmaceuticals.

Phio Pharmaceuticals首席执行官罗伯特·比特曼（RobertBitterman）说：“我们很高兴能在这五个临床地点进行研究，他们都对免疫肿瘤学非常感兴趣，并且是皮肤癌的领先中心。”。

PH-762 is an INTASYL compound that silences PD-1, a protein that inhibits T cells' ability to kill cancer cells. The Phase 1b trial is a non-comparative study of neoadjuvant monotherapy using PH-762 in adult patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. The study is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose or dose range for continued study of PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma..

PH-762是一种能够沉默PD-1（一种抑制T细胞杀死癌细胞能力的蛋白质）的INTASYL化合物。1b期临床试验是一项非比较性研究，对成年皮肤鳞状细胞癌，黑色素瘤或默克尔细胞癌患者使用PH-762进行新辅助单药治疗。该研究旨在评估肿瘤内注射PH-762新辅助使用的安全性和耐受性，评估肿瘤反应，并确定皮肤鳞状细胞癌，黑色素瘤或默克尔细胞癌患者继续研究PH-762的剂量或剂量范围。。

More information about this clinical trial is available at clinicaltrials.gov (identifier: NCT06014086).

有关该临床试验的更多信息，请访问clinicaltrials.gov（标识符：NCT06014086）。

About Phio Pharmaceuticals Corp.

关于Phio Pharmaceuticals Corp。

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics.

Phio Pharmaceuticals Corp.（纳斯达克：Phio）是一家临床阶段生物技术公司，其专有的INTASYL®siRNA基因沉默技术旨在使免疫细胞更有效地杀死肿瘤细胞。INTASYL是唯一专注于免疫肿瘤学治疗的自我递送RNAi技术。

INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems..

INTASYL药物精确地靶向特定的蛋白质，这些蛋白质会降低身体对抗癌症的能力，而不需要专门的配方或药物输送系统。。

For additional information, visit the Company's website, www.phiopharma.com.

有关更多信息，请访问该公司的网站www.phiopharma.com。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as 'intends,' 'believes,' 'anticipates,' 'indicates,' 'plans,' 'expects,' 'suggests,' 'may,' 'would,' 'should,' 'potential,' 'designed to,' 'will,' 'ongoing,' 'estimate,' 'forecast,' 'target,' 'predict,' 'could' and similar references, although not all forward-looking statements contain these words.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的前瞻性声明。前瞻性陈述可以用“意图”、“相信”、“预期”、“指示”、“计划”、“预期”、“建议”、“可能”、“会”、“应该”、“潜在”、“旨在”、“意志”、“正在进行”、“估计”、“预测”、“目标”、“预测”、“可能”和类似的引用来识别，尽管并非所有前瞻性陈述都包含这些词语。

These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Examples of forward-looking statements include statements regarding the timing of, as well as the progress of, and data reported from, this Phase 1b clinical trial and the therapeutic potential of PH-762 to treat patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma.

这些陈述仅基于我们目前的信念、期望和假设，并受到难以预测的固有不确定性、风险和环境变化的影响，其中许多不在我们的控制范围内。前瞻性陈述的例子包括关于该1b期临床试验的时间，进展和报告的数据以及PH-762治疗皮肤鳞状细胞癌，黑色素瘤或默克尔细胞癌患者的治疗潜力的陈述。

Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if appro.

由于许多重要因素，我们的实际结果可能与前瞻性声明中所示的结果存在重大差异，包括但不限于通货膨胀压力、利率上升、衰退恐惧、候选产品的开发、临床前和临床活动的结果、我们执行业务策略的能力、我们与合作伙伴开发候选产品的能力、任何此类合作的成功、将候选产品推进临床开发的时间表和持续时间、监管备案和批准的时间或可能性、我们成功将候选产品商业化的努力（如果批准）。

Contact:

联系人：

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp。

ir@phiopharma.com

ir@phiopharma.com

PR Contact

公关联系人

Michael Adams

迈克尔·亚当斯

Bridge View Media

Bridge View媒体

adams@bridgeviewmedia.com

adams@bridgeviewmedia.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/215533

要查看此新闻稿的源版本，请访问https://www.newsfilecorp.com/release/215533